Amal Aljuhani, Clinical Fellow at University of Toronto, shared a post on LinkedIn:
“Thrilled to share that our systematic review and meta-analysis on oral SERDs in HR+/HER2 advanced breast cancer has been accepted to ASCO 2026.
This work examines the evolving landscape of endocrine therapy, with a focus on ESR1 mutations as a key predictive biomarker across monotherapy, combination, and CDK4/6i-addition settings a question with real implications for how we sequence treatment in our patients.
I’m deeply grateful to my mentor Dr. Eitan Amir for his scientific rigor, his generosity in pushing this work forward, and for making me a better clinician-scientist with every conversation!
See you in Chicago.”
Other articles about ASCO 2026 on OncoDaily.